2008 ANNUAL REPORT
SciClone Pharmaceuticals, Inc.
950 Tower Lane, Suite 900
Foster City, CA 94404-2125
T: 650.358.3456 or 800.SCICLONE
Fax: 650.358.3469
SciClone Pharmaceuticals, Inc.
950 Tower Lane, Suite 900
Foster City, CA 94404-2125
T: 650.358.3456 or 800.SCICLONE
Fax: 650.358.3469
I n d e p e n d e n t A u d I t o r s Ernst & Young LLP Palo Alto, California L e g A L C o u n s e L DLA Piper US LLP San Francisco, California A n n u A L M e e t I n g
The Annual Meeting of Stockholders will be held on June 9, 2009 at 10 am PT at the Marriott San Mateo/San Francisco Airport, 1770 S. Amphlett Blvd., San Mateo, CA 94402. Detailed information about the meeting is contained in the Notice of Annual Meeting of Stockholders and Proxy Statement sent with a copy of the Annual Report on Form 10-K to each stockholder of record as of April 24, 2009. t r A d e M A r K s
SciClone, the SciClone logo, the Swirl logo and ZADAXIN are registered trademarks of SciClone Pharmaceuticals, Inc. in the United States and numerous other countries. F o r wA r d - L o o K I n g s tAt e M e n t s
This annual report contains forward-looking statements regarding development objectives and timing expecta-tions. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “might,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “contin-ues,” “forecast,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially. These risks and uncertainties include our ability to achieve our product revenue goals which may be affected by economic conditions, competition, regulatory restrictions and other matters, developments with respect to our clinical programs, the performance of our partners, vendors and other third parties with which we do business, our future cash requirements, and other matters. Please also refer to other risks and uncertainties described in SciClone’s filings with the Securities and Exchange Commission. All forward-looking statements are based on information currently available to SciClone and SciClone assumes no obligation to update any such forward-looking statements.
C o r p o r At e o F F I C e r s ( C o n t ’ d ) Trevor Jones, CBE, Ph.D. 2, 3 Commander of the British Empire and former Vice Chair of King’s College London
Gregg Lapointe4 Chief Executive Officer of Sigma-Tau Pharmaceuticals, Inc.
Ira Lawrence, M.D.4,5
Senior Vice President, Research and Development, Medicis Pharmaceuticals
Jon Saxe 1,3,4
Former President, PDL BioPharma, Inc. (formerly Protein Design Labs, Inc.) Former Vice President,
Hoffman-LaRoche Inc. C o r p o r At e H e A d Q u A r t e r s SciClone Pharmaceuticals, Inc. 950 Tower Lane, Suite 900 Foster City, CA 94404-2125 T: 650.358.3456 or 800.SCICLONE Fax: 650.358.3469 w e b s I t e
You can obtain recent press releases and other corporate information by visiting SciClone’s website at www.sciclone.com or
www.scicloneinternational.com A d d I t I o n A L I n F o r M At I o n
If you need additional assistance or informa-tion regarding the Company, or would like to receive a free copy of the Company’s 10-K or 10-Q reports filed with the Securities and Exchange Commission, please contact our Investor Relations department at 650.358.3437 or send an e-mail message to:
investorrelations@sciclone.com. C o M M o n s t o C K L I s t I n g
SciClone’s common stock trades on the NASDAQ Stock Market LLC under the symbol SCLN.
t r A n s F e r A g e n t
Communications concerning transfer require-ments, lost certifications, changes of address and other similar inquiries should be directed to SciClone’s transfer agent:
BNY Mellon Shareowner Services P.O. Box 358015 Pittsburgh, PA 15252-8015 T: 877.897.6928 Email: shrrelations@mellon.com www.melloninvestor.com/isd C o r p o r At e o F F I C e r s Friedhelm Blobel, Ph.D.
President and Chief Executive Officer
Gary Titus
Senior Vice President and Chief Financial Officer
Hans Schmid
President and Managing Director SciClone Pharmaceuticals International, Ltd.
Israel Rios, M.D.
Senior Vice President and Chief Medical Officer b o A r d o F d I r e C t o r s * Dean Woodman1,3,4 Chairman,
SciClone Pharmaceuticals, Inc. Co-Founder, Robertson Coleman Stephens & Woodman
Former Managing Director, ING Barings
John Baxter, M.D. 4 Professor of Medicine
University of California, San Francisco
Friedhelm Blobel, Ph.D.
President and Chief Executive Officer SciClone Pharmaceuticals, Inc.
Roberto Camerini, M.D. 5
Head of Clinical Research II-Worldwide Drug Development, for Sigma-Tau Industrie Farmaceutiche Riunite SpA
Richard Hawkins1,2,5
Chairman and Chief Executive Officer LabNow, Inc.
Rolf Henel 2,3
Partner, Naimark & Associates, Inc. *As of the Annual Meeting date and assuming the election of all nominees, SciClone will have eight directors consisting of Dean Woodman, Friedhelm Blobel, Roberto Camerini, Richard Hawkins, Trevor Jones, Gregg Lapointe, Ira Lawrence, and Jon Saxe. 1 Audit Committee Member
2 Compensation Committee Member 3 Nominating / Corporate Governance Committee Member
4 Business Development Committee Member 5 Scientific Review Committee Member
ZADAXIN P H A S E 1 P R O D U C T D E V E L O P M E N T P H A S E 2 P H A S E 3 M A R K E T E D DC BEAD RP101 Stage IV Melanoma U.S. / Europe China Pancreatic Cancer U.S. & Canada
HBV/HCV & Other Indications China, Russia & >30 other countries
SCV-07
HCV
Global (Ex-Russia)
Oral Mucositis in Head & Neck Cancer
Global (Ex-Russia)
sCICLone pHArMACeutICALs IS A PROFIT-DRIVEN BIOPHARMACEUTICAL COMPANY WITH A SUCCESSFUL INTERNATIONAL BUSINESS AND A PORTFOLIO OF NOVEL THERAPIES FOR CANCER AND INFECTIOUS DISEASES. WE ARE FOCUSED ON ACHIEVING INTERNATIONAL SALES GROWTH, A COST-CONTAINING CLINICAL DEVELOPMENT STRATEGY, AND TIGHT EXPENSE MANAGEMENT FOR THE BENEFIT OF OUR STOCKHOLDERS.
OUR LEAD PRODUCT, ZADAXIN®, IS SOLD IN OVER 30 COUNTRIES FOR THE TREATMENT OF HEPATITIS B AND
HEPATITIS C, CERTAIN CANCERS AND AS A VACCINE ADJUVANT. OUR PIPELINE OF PHASE 2 AND 3 DRUG CANDIDATES INCLUDES THYMALFASIN FOR STAGE IV MELANOMA FOR WHICH WE HAVE REACHED AGREEMENT WITH THE FDA ON THE DESIGN OF A PHASE 3 TRIAL; RP101 IN PHASE 2 FOR THE TREATMENT OF PANCREATIC CANCER; SCV-07 IN A PHASE 2 TRIAL FOR THE DELAY OF ONSET OF SEVERE ORAL MUCOSITIS IN PATIENTS RECEIVING CHEMORADIATION THERAPY FOR THE TREATMENT OF CANCERS OF THE HEAD AND NECK; AND,
D E A R S T O C K H O L D E R S ,
2008 was a year of remarkable revenue growth for SciClone. We achieved revenues of $54.1
million, an impressive growth of 46% over the prior year, largely driven by our China-based sales
organization. We plan to leverage and expand this international commercial success to obtain and
build profitability by growing our commercial activities through transactions focused on adding
new products as well as expanding into new geographic markets.
We are equally committed to advancing our phase 2 and 3 product portfolio in oncology and
infectious disease, two areas with great need for new therapeutic options for patients around the globe.
Our lead product ZADAXIN (thymalfasin or thymosin alpha 1), which is approved for sale in over
30 countries, is used in China primarily for the treatment of hepatitis B virus (HBV), liver cancer
and other related cancers. We expect revenue growth for ZADAXIN to continue in 2009 and beyond.
For more than ten years we have been building a strong sales and marketing organization in China,
which we believe positions us for continued success as we seek to in-license additional therapeutics
for our international business. We have already acquired exclusive Chinese marketing rights to DC
Bead and are pursuing regulatory approval for this product in liver cancer, one of the most prevalent
and deadly cancers in China, with the objective of extending this product’s indications to colorectal
cancer as well. We expect to launch this product in 2009. We intend to broaden our product
portfolio further by in-licensing or acquiring the marketing rights to other synergistic, commercially
attractive products in China.
FROm LEFT TO RigHT: Hans Schmid, Managing
Director and President, SciClone Pharmaceuticals International, Ltd.; israel
Rios, m.D., Senior Vice
President And Chief Medical Officer; Cynthia Tuthill, Ph.D., Senior Vice President and Chief Scientific Officer;
gary Titus, Senior Vice
President and Chief Financial Officer; Jeffery Lange, Vice President, Business Development; Friedhelm
Blobel, Ph.D., President and
Chief Executive Officer, SciClone Pharmaceuticals, Inc.;
Craig Halverson, Vice President,
Regulatory Affairs & Quality Assurance.
$70.0 60.0 50.0 40.0 30.0 20.0 10.0 0 2005 2006 2007 2008 2009E REVENUE ($ IN MILLIONS)
As we strive to achieve profitability, it is vital that we make strategic and cost-effective decisions
regarding the development and advancement of our pipeline. Our clinical development strategy is
now focused on creating stockholder value by driving cost-efficient phase 1 and 2 development of
promising compounds, while seeking development partners for costly phase 3 trials, allowing us to
achieve the potential upside of a biotechnology business from our portfolio of drug candidates.
Our phase 3-ready product candidate, thymalfasin, has shown compelling efficacy in hepatitis B
and immune-sensitive cancers, such as melanoma. We have made significant progress to date with
our development program for thymalfasin in stage IV melanoma, including reaching an agreement
in late 2008 with the U.S. Food and Drug Administration (FDA), on a Special Protocol
Assessment on the design of a phase 3 registration trial for this disease.
Thymalfasin has been granted Orphan Drug Designation by the U.S. FDA for the treatment of
stage IIb through stage IV melanoma. The Orphan Drug Designation will allow us a seven-year
period of market exclusivity if thymalfasin is approved for this indication in the United States. We
have also applied for, but have not yet been issued a patent with respect to the use of thymalfasin
as a therapy for melanoma. Our goal for this program is to identify a collaborative partner before
beginning the phase 3 trial.
Current therapies for melanoma are ineffective at extending survival, which is typically only six
to nine months for patients with stage IV melanoma, and we believe that thymalfasin has the
potential to provide a better treatment option for patients. We estimate the worldwide market
for stage IV melanoma to be $200 million, with a much larger additional market potential in the
adjuvant setting.
Also in our oncology product portfolio, we are particularly hopeful about our drug in
development, RP101, for pancreatic cancer, an aggressive and devastating disease that continues
to be a significant unmet medical need for patients in North America and around the world. We
were excited to announce in March of 2009 that we completed enrollment ahead of schedule in
our phase 2 clinical trial for RP101 in patients with this disease. RP101 has been granted Orphan
Drug Designation by the U.S. FDA for the adjunct treatment of pancreatic cancer.
Previous data on RP101 have indicated that the drug, a nucleoside analog also known as BVdU,
may help to extend the beneficial tumor-fighting effects of chemotherapy. We expect to report
results from this phase 2 trial in the first half of 2010.
Pancreatic cancer is one of the deadliest forms of cancer. The American Cancer Society estimates
that in 2009, pancreatic cancer is expected to claim as many as 33,000 lives in the U.S.
alone. There are few treatment options for these patients, who quickly develop resistance to
chemotherapy, so there is an urgent need to find new treatment solutions. We expect that RP101
could offer a significant clinical benefit to patients, with a U.S. potential market opportunity of
approximately $350 million.
In addition to RP101, we have a phase 2 clinical program ongoing with SCV-07 in oncology.
SCV-07 is a synthetic peptide with immune stimulating effects. In December 2008, SCV-07
entered a phase 2 safety and efficacy trial to assess the ability of SCV-07 to delay the onset of
severe oral mucositis in patients receiving chemoradiation therapy for the treatment of cancers of
the head and neck, and we expect to complete enrollment for SCV-07 in oral mucositis in 2009.
SCV-07 also demonstrated encouraging antiviral activity in a phase 2a clinical trial as a sole agent
administered to patients chronically infected with HCV. During 2009, we plan to initiate a phase
2 clinical trial of SCV-07 for the treatment of patients with HCV.
It has been a year of tremendous progress at SciClone, and we believe that our momentum
is building. Our goals for the next twelve months are substantial. We plan to continue
cost-containing clinical development strategies and tight expense management, and are focused on
achieving and sustaining profitability - no small feat for a biopharmaceutical company in today’s
uncertain market environment. In 2009, we also plan to complete enrollment for SCV-07 in oral
mucositis, in-license an additional product for the international market with a continuing strong
focus on China, and establish a partnership for our melanoma development program.
We would like to express our sincere appreciation to our investors for their continued support,
particularly in this difficult financial climate. We are well-positioned to move ahead this year with
our focus on profitability, particularly now that we have resolved the director election contest with
our long standing partner Sigma-Tau and we welcome three directors nominated by them to our
Board of Directors. Our primary focus in 2009 and beyond will be on continuing to build value for
our stockholders, and we look forward to communicating our progress with you regularly during
the coming year as we continue to achieve new commercial milestones and report clinical results.
Finally, I would like to thank the team at SciClone for their hard work and dedication to
achieving our goals in 2008 and their commitment to the future, with special thanks to our
well-established sales organization in China. 2008 was a transformative year in our Company’s history,
and we are working towards another year of significant progress and strong value creation for our
stockholders in 2009.
Friedhelm Blobel, Ph.D.
President and Chief Executive Officer
May 1, 2009
SCV-07 SCV-07
Radiation Damaged Cells STAT3 STAT3 MACROPHAGE / DENDRITIC CELL MACROPHAGE / DENDRITIC CELL protects: normal tissue from radiation inhibits: IL-6, IL-10, VEGF production promotes: IL-12, IL-2 production promotes: neopterin production, dendritic cell maturation
inhibits: T-Reg cells which suppress immune function T-Reg Cell Natural Killer (NK) cell Cytotoxic T (CTL) Cell T Helper (CD4+ ) Cell Free Floating Viruses ATTA CK ATTA CK AT TA CK Virally Infected Cells Virally Infected Cells Tumor
Cells Tumor Cells
SCV-07: MULTIPLE IMMUNE MODULATING EFFECTS
CHEMOTHERAPY
RP101
RP101
Tumors killed via: Apoptosis Damage to DNA Antitumor immunity Decreased replication
RP101 prevents tumors from developing chemoresistance via blocking changes in gene expression: Block apoptosis evasion
(STAT3, JUN-D, DDX1) Block DNA repair
(APEX, UBE2N) Block replication, angiogenesis
(VEGF, IL-10) Improve antitumor immunity
(LTA, LTB, NK4, ICAM-1, TNSF14/LIGHT) Decrease extrusion pumps
Tumors develop chemoresistance via changes in gene expression: Evade apoptosis Improve DNA repair Decrease immunity Increase replication, angiogenesis Increase extrusion pumps RP101: BLOCKS RESISTANCE TO CHEMOTHERAPY
Tumor Cells Tumor Cells
Tumor Cells Tumor Cells
2008 ANNUAL REPORT
SciClone Pharmaceuticals, Inc.
950 Tower Lane, Suite 900
Foster City, CA 94404-2125
T: 650.358.3456 or 800.SCICLONE
Fax: 650.358.3469
SciClone Pharmaceuticals, Inc.
950 Tower Lane, Suite 900
Foster City, CA 94404-2125
T: 650.358.3456 or 800.SCICLONE
Fax: 650.358.3469
I n d e p e n d e n t A u d I t o r s Ernst & Young LLP Palo Alto, California L e g A L C o u n s e L DLA Piper US LLP San Francisco, California A n n u A L M e e t I n g
The Annual Meeting of Stockholders will be held on June 9, 2009 at 10 am PT at the Marriott San Mateo/San Francisco Airport, 1770 S. Amphlett Blvd., San Mateo, CA 94402. Detailed information about the meeting is contained in the Notice of Annual Meeting of Stockholders and Proxy Statement sent with a copy of the Annual Report on Form 10-K to each stockholder of record as of April 24, 2009. t r A d e M A r K s
SciClone, the SciClone logo, the Swirl logo and ZADAXIN are registered trademarks of SciClone Pharmaceuticals, Inc. in the United States and numerous other countries. F o r wA r d - L o o K I n g s tAt e M e n t s
This annual report contains forward-looking statements regarding development objectives and timing expecta-tions. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “might,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “contin-ues,” “forecast,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially. These risks and uncertainties include our ability to achieve our product revenue goals which may be affected by economic conditions, competition, regulatory restrictions and other matters, developments with respect to our clinical programs, the performance of our partners, vendors and other third parties with which we do business, our future cash requirements, and other matters. Please also refer to other risks and uncertainties described in SciClone’s filings with the Securities and Exchange Commission. All forward-looking statements are based on information currently available to SciClone and SciClone assumes no obligation to update any such forward-looking statements.
C o r p o r At e o F F I C e r s ( C o n t ’ d ) Trevor Jones, CBE, Ph.D. 2, 3 Commander of the British Empire and former Vice Chair of King’s College London
Gregg Lapointe4 Chief Executive Officer of Sigma-Tau Pharmaceuticals, Inc.
Ira Lawrence, M.D.4,5
Senior Vice President, Research and Development, Medicis Pharmaceuticals
Jon Saxe 1,3,4
Former President, PDL BioPharma, Inc. (formerly Protein Design Labs, Inc.) Former Vice President,
Hoffman-LaRoche Inc. C o r p o r At e H e A d Q u A r t e r s SciClone Pharmaceuticals, Inc. 950 Tower Lane, Suite 900 Foster City, CA 94404-2125 T: 650.358.3456 or 800.SCICLONE Fax: 650.358.3469 w e b s I t e
You can obtain recent press releases and other corporate information by visiting SciClone’s website at www.sciclone.com or
www.scicloneinternational.com A d d I t I o n A L I n F o r M At I o n
If you need additional assistance or informa-tion regarding the Company, or would like to receive a free copy of the Company’s 10-K or 10-Q reports filed with the Securities and Exchange Commission, please contact our Investor Relations department at 650.358.3437 or send an e-mail message to:
investorrelations@sciclone.com. C o M M o n s t o C K L I s t I n g
SciClone’s common stock trades on the NASDAQ Stock Market LLC under the symbol SCLN.
t r A n s F e r A g e n t
Communications concerning transfer require-ments, lost certifications, changes of address and other similar inquiries should be directed to SciClone’s transfer agent:
BNY Mellon Shareowner Services P.O. Box 358015 Pittsburgh, PA 15252-8015 T: 877.897.6928 Email: shrrelations@mellon.com www.melloninvestor.com/isd C o r p o r At e o F F I C e r s Friedhelm Blobel, Ph.D.
President and Chief Executive Officer
Gary Titus
Senior Vice President and Chief Financial Officer
Hans Schmid
President and Managing Director SciClone Pharmaceuticals International, Ltd.
Israel Rios, M.D.
Senior Vice President and Chief Medical Officer b o A r d o F d I r e C t o r s * Dean Woodman1,3,4 Chairman,
SciClone Pharmaceuticals, Inc. Co-Founder, Robertson Coleman Stephens & Woodman
Former Managing Director, ING Barings
John Baxter, M.D. 4 Professor of Medicine
University of California, San Francisco
Friedhelm Blobel, Ph.D.
President and Chief Executive Officer SciClone Pharmaceuticals, Inc.
Roberto Camerini, M.D. 5
Head of Clinical Research II-Worldwide Drug Development, for Sigma-Tau Industrie Farmaceutiche Riunite SpA
Richard Hawkins1,2,5
Chairman and Chief Executive Officer LabNow, Inc.
Rolf Henel 2,3
Partner, Naimark & Associates, Inc. *As of the Annual Meeting date and assuming the election of all nominees, SciClone will have eight directors consisting of Dean Woodman, Friedhelm Blobel, Roberto Camerini, Richard Hawkins, Trevor Jones, Gregg Lapointe, Ira Lawrence, and Jon Saxe. 1 Audit Committee Member
2 Compensation Committee Member 3 Nominating / Corporate Governance Committee Member
4 Business Development Committee Member 5 Scientific Review Committee Member
2008 ANNUAL REPORT
SciClone Pharmaceuticals, Inc.
950 Tower Lane, Suite 900
Foster City, CA 94404-2125
T: 650.358.3456 or 800.SCICLONE
Fax: 650.358.3469
SciClone Pharmaceuticals, Inc.
950 Tower Lane, Suite 900
Foster City, CA 94404-2125
T: 650.358.3456 or 800.SCICLONE
Fax: 650.358.3469
I n d e p e n d e n t A u d I t o r s Ernst & Young LLP Palo Alto, California L e g A L C o u n s e L DLA Piper US LLP San Francisco, California A n n u A L M e e t I n g
The Annual Meeting of Stockholders will be held on June 9, 2009 at 10 am PT at the Marriott San Mateo/San Francisco Airport, 1770 S. Amphlett Blvd., San Mateo, CA 94402. Detailed information about the meeting is contained in the Notice of Annual Meeting of Stockholders and Proxy Statement sent with a copy of the Annual Report on Form 10-K to each stockholder of record as of April 24, 2009. t r A d e M A r K s
SciClone, the SciClone logo, the Swirl logo and ZADAXIN are registered trademarks of SciClone Pharmaceuticals, Inc. in the United States and numerous other countries. F o r wA r d - L o o K I n g s tAt e M e n t s
This annual report contains forward-looking statements regarding development objectives and timing expecta-tions. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “might,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “contin-ues,” “forecast,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially. These risks and uncertainties include our ability to achieve our product revenue goals which may be affected by economic conditions, competition, regulatory restrictions and other matters, developments with respect to our clinical programs, the performance of our partners, vendors and other third parties with which we do business, our future cash requirements, and other matters. Please also refer to other risks and uncertainties described in SciClone’s filings with the Securities and Exchange Commission. All forward-looking statements are based on information currently available to SciClone and SciClone assumes no obligation to update any such forward-looking statements.
C o r p o r At e o F F I C e r s ( C o n t ’ d ) Trevor Jones, CBE, Ph.D. 2, 3 Commander of the British Empire and former Vice Chair of King’s College London
Gregg Lapointe4 Chief Executive Officer of Sigma-Tau Pharmaceuticals, Inc.
Ira Lawrence, M.D.4,5
Senior Vice President, Research and Development, Medicis Pharmaceuticals
Jon Saxe 1,3,4
Former President, PDL BioPharma, Inc. (formerly Protein Design Labs, Inc.) Former Vice President,
Hoffman-LaRoche Inc. C o r p o r At e H e A d Q u A r t e r s SciClone Pharmaceuticals, Inc. 950 Tower Lane, Suite 900 Foster City, CA 94404-2125 T: 650.358.3456 or 800.SCICLONE Fax: 650.358.3469 w e b s I t e
You can obtain recent press releases and other corporate information by visiting SciClone’s website at www.sciclone.com or
www.scicloneinternational.com A d d I t I o n A L I n F o r M At I o n
If you need additional assistance or informa-tion regarding the Company, or would like to receive a free copy of the Company’s 10-K or 10-Q reports filed with the Securities and Exchange Commission, please contact our Investor Relations department at 650.358.3437 or send an e-mail message to:
investorrelations@sciclone.com. C o M M o n s t o C K L I s t I n g
SciClone’s common stock trades on the NASDAQ Stock Market LLC under the symbol SCLN.
t r A n s F e r A g e n t
Communications concerning transfer require-ments, lost certifications, changes of address and other similar inquiries should be directed to SciClone’s transfer agent:
BNY Mellon Shareowner Services P.O. Box 358015 Pittsburgh, PA 15252-8015 T: 877.897.6928 Email: shrrelations@mellon.com www.melloninvestor.com/isd C o r p o r At e o F F I C e r s Friedhelm Blobel, Ph.D.
President and Chief Executive Officer
Gary Titus
Senior Vice President and Chief Financial Officer
Hans Schmid
President and Managing Director SciClone Pharmaceuticals International, Ltd.
Israel Rios, M.D.
Senior Vice President and Chief Medical Officer b o A r d o F d I r e C t o r s * Dean Woodman1,3,4 Chairman,
SciClone Pharmaceuticals, Inc. Co-Founder, Robertson Coleman Stephens & Woodman
Former Managing Director, ING Barings
John Baxter, M.D. 4 Professor of Medicine
University of California, San Francisco
Friedhelm Blobel, Ph.D.
President and Chief Executive Officer SciClone Pharmaceuticals, Inc.
Roberto Camerini, M.D. 5
Head of Clinical Research II-Worldwide Drug Development, for Sigma-Tau Industrie Farmaceutiche Riunite SpA
Richard Hawkins1,2,5
Chairman and Chief Executive Officer LabNow, Inc.
Rolf Henel 2,3
Partner, Naimark & Associates, Inc. *As of the Annual Meeting date and assuming the election of all nominees, SciClone will have eight directors consisting of Dean Woodman, Friedhelm Blobel, Roberto Camerini, Richard Hawkins, Trevor Jones, Gregg Lapointe, Ira Lawrence, and Jon Saxe. 1 Audit Committee Member
2 Compensation Committee Member 3 Nominating / Corporate Governance Committee Member
4 Business Development Committee Member 5 Scientific Review Committee Member
